These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11404515)

  • 21. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric HIV costs across three treatment eras from 1986 to 2007.
    Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
    Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of HIV medical care in the era of highly active antiretroviral therapy.
    Gebo KA; Chaisson RE; Folkemer JG; Bartlett JG; Moore RD
    AIDS; 1999 May; 13(8):963-9. PubMed ID: 10371178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.
    Beck EJ; Mandalia S; Griffith R; Beecham J; Walters MD; Boulton M; Miller DL
    Pharmacoeconomics; 2000 Jan; 17(1):53-69. PubMed ID: 10747765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand.
    Kitajima T; Kobayashi Y; Chaipah W; Sato H; Chadbunchachai W; Thuennadee R
    AIDS; 2003 Nov; 17(16):2375-81. PubMed ID: 14571190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
    Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
    Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 Window Trial.
    Charreau I; Jeanblanc G; Tangre P; Boyer L; Saouzanet M; Marchou B; Molina JM; Aboulker JP; Durand-Zaleski I;
    J Acquir Immune Defic Syndr; 2008 Dec; 49(4):416-21. PubMed ID: 18931625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
    Kousignian I; Abgrall S; Duval X; Descamps D; Matheron S; Costagliola D;
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):50-7. PubMed ID: 14501793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.
    Hubben GA; Bishai D; Pechlivanoglou P; Cattelan AM; Grisetti R; Facchin C; Compostella FA; Bos JM; Postma MJ; Tramarin A
    AIDS Care; 2008 Apr; 20(4):449-55. PubMed ID: 18449822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated direct costs of medical care for HIV-infected patients within a regional population from 2006 to 2017.
    Krentz HB; Vu Q; Gill MJ
    HIV Med; 2020 May; 21(5):289-298. PubMed ID: 31852032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV antiretroviral treatment: early versus later.
    Mauskopf J; Kitahata M; Kauf T; Richter A; Tolson J
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):562-9. PubMed ID: 16044008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.
    Sansom SL; Anthony MN; Garland WH; Squires KE; Witt MD; Kovacs Andrea A; Larsen RA; Valencia R; Pals SL; Hader S; Weidle PJ; Wohl AR
    AIDS Patient Care STDS; 2008 Feb; 22(2):131-8. PubMed ID: 18260804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center.
    Mole L; Ockrim K; Holodniy M
    Pharmacoeconomics; 1999 Sep; 16(3):307-15. PubMed ID: 10558042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.
    Vijayaraghavan A; Efrusy MB; Mazonson PD; Ebrahim O; Sanne IM; Santas CC
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):91-100. PubMed ID: 17621241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.